This brand name is authorized in Nigeria.
The drug OXYNIC contains a combination of these active pharmaceutical ingredients (APIs):
1
|
UNII
544Y3D6MYH - AMOXICILLIN SODIUM
|
|
Amoxicillin is a semisynthetic penicillin (beta-lactam antibiotic) that inhibits one or more enzymes (often referred to as penicillin-binding proteins, PBPs) in the biosynthetic pathway of bactericidal peptidoglycan, which is an integral structural component of the bacterial cell wall. Inhibition of peptidoglycan synthesis leads to weakening of the cell wall, which is usually followed by cell lysis and death. |
|
2
|
UNII
Q42OMW3AT8 - CLAVULANATE POTASSIUM
|
|
Clavulanic acid is a beta-lactam structurally related to penicillins. It inactivates some beta-lactamase enzymes thereby preventing inactivation of amoxicillin. |
|
This drug has been approved in Nigeria as follows:
| Identifier | Form | Presentation | Description | Approval |
|---|---|---|---|---|
| B4-6169 | Tablet | Oxynic 625 tablets TAB 500 mg; 125 mg | Oxynic 625 tablets B4-6169 Oxynic 625 tablets Amoxicillin Trihydrate BP 500mg, Potassium Clavulanate BP 125mg POM 1 GBGL PHARMA LIMITED, OGUNTONA CRESCENT GBAGADA PHASE 1 LAGOS LAGOS FINECURE PHARMACEUTICAL LTD, VILLAGE SHIMLA PISTAUR, MALSA ROAD, KICHHA, UDHAMSINGH NAGAR, UTTARAKHAND-263148,INDIA, India 2/23/2023 2/22/2028 | 23/02/2023 |
| B4-6874 | Tablet | Oxynic 1000 tablets TAB 875 mg; 125 mg | Oxynic 1000 tablets B4-6874 Oxynic 1000 tablets Amoxicillin Trihydrate BP 875mg, Potassium Clavulanate BP 125mg Tablet POM 1 GBGL PHARMA LIMITED, OGUNTONA CRESCENT GBAGADA PHASE 1 LAGOS LAGOS Nigeria FINECURE PHARMACEUTICAL LTD, VILLAGE SHIMLA PISTAUR, MALSA ROAD, KICHHA, UDHAMSINGH NAGAR, UTTARAKHAND-263148,INDIA, India 26/01/2023 25/01/2028 | 26/01/2023 |
| B4-7281 | Powder for suspension | Oxynic 312.5g powder for oral suspension PWD_F_SOL 250 mg; 62.5 mg 1x70ml | 62 RNW-PP-258734 oxynic 312.5g powder for oral suspension AMOXICILLIN TRIHYDRATE Amoxicillin Trihydrate BP 250mg, Potassium Clavulanate BP 62.5 (EXCIPIENTS: Colloidal Anhydrous Silica BP, Hypromellose BP, Xanthan Gum BP, Aspartame BP, Citric Acid BP, Sodium Benzoate BP, Sodium Benzoate BP, Sodium Benzoate BP) B4-7281 Drugs Imported Products 1x70ml POM 1 6/16/2022 GBGL PHARMA LIMITED, OGUNTONA CRESCENT GBAGADA PHASE 1 LAGOS LAGOS 25432112 gbglpharmaltd2018@outlook.com FINECURE PHARMACEUTICALS LIMITED, SHIMLA PISTAUR, MALSA ROAD, KICHHA, UDHAM SINGH NAGAR, UTTARAKHAND-263148, INDIA, India | 30/12/2023 |
| C4-0358 | Powder for injection | Oxynic-600 Injection INJ_PWD 500 mg; 100 mg | Powder for solution for injection in a vial Each vial contains: Amoxicillin Sodium equiv. to Amoxicillin 500 mg, Clavulanate Potassium equiv. to Clavulanic Acid 100 mg | 20/12/2019 |
| C4-0359 | Powder for injection | Oxynic-1.2 Injection INJ_PWD 1000 mg; 200 mg | Powder for solution for injection in a vial Each vial contains: Amoxicillin Sodium equiv. to Amoxicillin 1000 mg, Clavulanate Potassium equiv. to Clavulanic Acid 200 mg | 20/12/2019 |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC Group | Classification | |
|---|---|---|
| J01CR02 | Amoxicillin and enzyme inhibitor | J Antiinfectives for systemic use → J01 Antibacterials for systemic use → J01C Beta-lactam antibacterials, penicillins → J01CR Combinations of penicillins, incl. beta-lactamase inhibitors |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| NG | Registered Drug Product Database | B4-6169, B4-6874, B4-7281, C4-0358, C4-0359 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.